PEG 400

DRUG2 trials

Sponsors

Boehringer Ingelheim

Conditions

Healthy

Phase 1

A Safety, Tolerability and Preliminary Pharmacokinetics of BILR 355 BS Single-rising Dose Study in Healthy Male Volunteers

CompletedNCT02254538

Boehringer IngelheimHealthy

Start: 2002-05-31Updated: 2014-10-02

Safety of Total Daily Doses of Polyethylene Glycol (PEG) 400 Administered Orally to Healthy Male Human Subjects

CompletedNCT02260076

Boehringer IngelheimHealthy

Start: 2001-09-30Updated: 2014-10-09